^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EO-3021

    i
    Other names: CPO 102, EO 3021, SYSA 1801, EO-3021, CPO102, SYSA1801, CPO-102, EO3021, SYSA-1801
    Company:
    CSPC Pharma, Elevation Oncology
    Drug class:
    Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    1year
    A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2. (ASCO-GI 2024)
    41, 2023. Clinical trial information: NCT05980416.
    Clinical • P1 data
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over1year
    Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=0, Withdrawn, Conjupro Biotherapeutics, Inc. | N=72 --> 0 | Trial completion date: Mar 2025 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2025 --> Nov 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN1 positive
    |
    EO-3021
    over1year
    Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (clinicaltrials.gov)
    P1, N=120, Recruiting, Elevation Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over1year
    Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Elevation Oncology
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over1year
    First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. (ASCO 2023)
    SYSA1801 shows promising early signs of efficacy with a well-tolerated safety profile in pts with CLDN18.2-expressing resistant/refractory solid tumors, especially GC. Part 1 of the study is ongoing with part 2 to start when the optimized dose is determined in China; studies outside of Greater China including in the United States are being planned by Elevation Oncology. Clinical trial information: NCT05009966.
    Clinical • P1 data
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    3years
    Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=272, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021
    over3years
    Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Conjupro Biotherapeutics, Inc.
    Clinical • New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    EO-3021
    over3years
    Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (clinicaltrials.gov)
    P1, N=272, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    EO-3021